Astellas Venture Management LLC β 2024 Investments
2 investments dated 2024 Β· listed companies and verified rows first Β· show all
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)inKEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalCambridge Innovation CapitalLongwood FundSR One Capital ManagementSV Health InvestorsVertex Ventures HC
PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
BiotechMedical DevicesCambridge, GB
Co-investorsAmadeus Capital PartnersCambridge Angels groupUniversity of Cambridge EnterpriseAmadeus Capital SAO2h VenturesParkwalk Advisors
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.